• Results for the Fourth Quarter 2016

    Currency neutral sales of own products decreased with 3 MNOK or 5.7 % due in part to a back order situation on TTFM flow probes. Currency neutral sales of own products increased with 9.5 %…

    Read more
  • Results for the Third Quarter 2016

    Sales in the 3rd quarter ended at MNOK 67.9 (MNOK 61.6), a 10.2 % increase. USA had a strong quarter with an 18.5% growth in sales. In Asia sales increased with 83.6 % while in…

    Read more
  • Results for the First Quarter 2016

    Sales for the quarter ended at MNOK 65.5 which is a 13.1 % sales growth for the quarter. Sales of own products increased with 28.8 % to MNOK 49.1 and US sales up 42.8 %…

    Read more
  • Medistim Delivers Best Quarter Ever

    Medistim delivers its best quarter ever and sales ended at MNOK 66.1 (MNOK 52.2), a growth of 26.6 %. Sales for 2014 ended at MNOK 214.8 (MNOK 191.0), a growth of 12.5 %. The atrong…

    Read more
  • Results for the Third Quarter 2014

    Sales for the quarter ended at MNOK 52.0 (MNOK 44.3), a growth of 17 %. Sales as of September ended at MNOK 148.7 (MNOK 138.8), a growth of 7.1 %. • Continued strong growth in…

    Read more
  • MiraQ™ Cardiac Launched in the European Market

    (Oslo, 13 October 2014) Medistim ASA (OSE: MEDI), a Norwegian company that develops and commercializes medical equipment for use in cardiac, vascular and transplant surgery, announces that they launch its new product MiraQ Cardiac in…

    Read more
  • Results for the Second Quarter and First Half 2014

    Sales ended at MNOK 47.9 for the quarter (MNOK 49.0). Sales for the 1st half increased by 2.3 % and ended at MNOK 96.7 (MNOK 94.5). (more…)

    Read more
  • Results for the First Quarter 2014

    Sales for the quarter ended at MNOK 48.9 (MNOK 45.5) and operating profit (EBIT) ended at MNOK 7.2 (MNOK 7.3). It was a strong development in imaging sales with a 67 % increase in capital sales.…

    Read more
  • Record Sales in Fourth Quarter 2013

    Medistim delivers record sales for a quarter with MNOK 52.2 (MNOK 49.7). Sales for 2013 ended at MNOK 191 (MNOK 183.8), which is a 3.9 % growth. Operating profit (EBIT) for the quarter ended at…

    Read more
  • Q1 2013 financial report

    Medistim reports sales revenues of MNOK 45,5 (45,1) and operating result of MNOK 7,3 (7,6) in the first quarter of 2013. The positive development in the USA continues, with 14% growth in revenues. The General…

    Read more